<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; organization</title>
	<atom:link href="http://www.tapanray.in/tag/organization/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Leadership Challenge In Post Covid Paradigm</title>
		<link>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-leadership-challenge-in-post-covid-paradigm</link>
		<comments>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/#comments</comments>
		<pubDate>Mon, 03 Oct 2022 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field]]></category>
		<category><![CDATA[focussed]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[post covid]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[presence]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10713</guid>
		<description><![CDATA[Bringing a long cherished relief to many, on September 15, 2022, the World Health Organization said, &#8216;we can see the Finish Line&#8217; for the COVID-19 pandemic but it&#8217;s not over yet’. As I see today, several things are changing pretty fast &#8230; <a href="http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fostering EQ For Pharma’s Excellence In The New Normal</title>
		<link>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fostering-eq-for-pharmas-excellence-in-the-new-normal</link>
		<comments>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 01 Mar 2021 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cutting-edge]]></category>
		<category><![CDATA[disruption]]></category>
		<category><![CDATA[EI]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[EQ]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[quotient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[sign]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[telltale]]></category>
		<category><![CDATA[unprecedented]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10427</guid>
		<description><![CDATA[On February 25, 2021, one of the top Indian business daily flashed a headline &#8211; “It will be working from home, post-pandemic too at many top companies.” It wrote, companies like, Tata Steel, Philips, Infosys and Maruti Suzuki are evaluating job roles to &#8230; <a href="http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fostering-eq-for-pharmas-excellence-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Pharma Industry A Late Learner, Always?</title>
		<link>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-pharma-industry-a-late-learner-always</link>
		<comments>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/#comments</comments>
		<pubDate>Mon, 23 Dec 2019 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[diagnosis]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[E-Patients]]></category>
		<category><![CDATA[empowerment]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[episodes]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fast]]></category>
		<category><![CDATA[Ferguson]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[late]]></category>
		<category><![CDATA[learner]]></category>
		<category><![CDATA[learning]]></category>
		<category><![CDATA[legacy]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reinvent the wheel]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thomas]]></category>
		<category><![CDATA[touchpoints]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9826</guid>
		<description><![CDATA[Several upcoming concepts in the pharmaceutical industry are becoming buzzwords today. But, most of these were recommended by stalwarts several decades ago. Interestingly, the prevailing scenario is no different, even related to wide-scale adoption of a number of cutting-edge technologies, &#8230; <a href="http://www.tapanray.in/is-pharma-industry-a-late-learner-always/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-pharma-industry-a-late-learner-always/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>While Pharma Leadership Change This Atypical Skill Counts</title>
		<link>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=while-pharma-leadership-change-this-atypical-skill-counts</link>
		<comments>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/#comments</comments>
		<pubDate>Mon, 01 Jul 2019 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[demand]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digital first]]></category>
		<category><![CDATA[hardware]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[software]]></category>
		<category><![CDATA[Space]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[touchpoint]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9613</guid>
		<description><![CDATA[Effective September 01, 2019, the global pharma major Sanofi will have a new CEO, as the present CEO retires attaining his retirement age of 65 years. This appears to be a mandatory announcement from the company, as is required during the &#8230; <a href="http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/while-pharma-leadership-change-this-atypical-skill-counts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why D&amp;I Is A Powerful Growth Driver For Pharma Industry</title>
		<link>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-di-is-a-powerful-growth-driver-for-pharma-industry</link>
		<comments>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/#comments</comments>
		<pubDate>Mon, 10 Jun 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accountability.]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[empathetic]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[facets]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[society]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9578</guid>
		<description><![CDATA[‘Diverse India’ now needs an ‘inclusive society’, vowed the Prime Minister of India, after his massive electoral win on May 23, 2019. Many may consider a part of it as rhetoric, notwithstanding, as and when the government policy of Diversity and Inclusion &#8230; <a href="http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-di-is-a-powerful-growth-driver-for-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Creative Is Pharma Industry?</title>
		<link>http://www.tapanray.in/how-creative-is-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-creative-is-pharma-industry</link>
		<comments>http://www.tapanray.in/how-creative-is-pharma-industry/#comments</comments>
		<pubDate>Mon, 15 Apr 2019 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[creativity]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[gross]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mother]]></category>
		<category><![CDATA[necessity]]></category>
		<category><![CDATA[Operating]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9482</guid>
		<description><![CDATA[“Because the purpose of business is to create a customer, the business enterprise has two – and only two – basic functions: marketing and innovation. Marketing and innovation produce results; all the rest are costs. Marketing is the distinguishing, unique &#8230; <a href="http://www.tapanray.in/how-creative-is-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-creative-is-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Pharma Marketing Combo Places Patients At The Center Of Business</title>
		<link>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-pharma-marketing-combo-places-patients-at-the-center-of-business</link>
		<comments>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/#comments</comments>
		<pubDate>Mon, 01 Apr 2019 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[behavioral]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[combo]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[science]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9464</guid>
		<description><![CDATA[As discussed in several of my previous articles, most pharma players need to walk the talk on ‘patient-centricity&#8217;, coming out of prevailing high decibel lip-service. This is not an easy task, and far from being every company’s cup of tea. Effective &#8230; <a href="http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-pharma-marketing-combo-places-patients-at-the-center-of-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Design Thinking’: Translating Struggles into Positive Outcomes in Pharma</title>
		<link>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=design-thinking-translating-struggles-into-positive-outcomes-in-pharma</link>
		<comments>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/#comments</comments>
		<pubDate>Mon, 24 Sep 2018 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[design]]></category>
		<category><![CDATA[Design thinking]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[prototype]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[solving]]></category>
		<category><![CDATA[struggles]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[thinking]]></category>
		<category><![CDATA[UCB]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9196</guid>
		<description><![CDATA[Problems of various nature will keep coming on business, as long as long as one remains in the business. It doesn’t spare anyone in the organization – from the very top to right up to the very bottom. All is &#8230; <a href="http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/design-thinking-translating-struggles-into-positive-outcomes-in-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Diversity And Inclusion’: A Missing Link For Indian Pharma</title>
		<link>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=diversity-and-inclusion-a-missing-link-for-indian-pharma</link>
		<comments>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/#comments</comments>
		<pubDate>Mon, 25 Jun 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[culture]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[link]]></category>
		<category><![CDATA[Missing]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[oriented]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9015</guid>
		<description><![CDATA[Inadequate access to affordable health care to a vast majority of the population has been a favorite topic of debate, since long, globally. This discourse is generally centered around the least developed and the developing world, such as India. However, &#8230; <a href="http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/diversity-and-inclusion-a-missing-link-for-indian-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patient Services Aren’t Optional Any More For Pharma Business Excellence</title>
		<link>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patient-services-arent-optional-any-more-for-pharma-business-excellence</link>
		<comments>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/#comments</comments>
		<pubDate>Mon, 20 Mar 2017 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[conflict]]></category>
		<category><![CDATA[device]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[excellence]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[optional]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[providers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8140</guid>
		<description><![CDATA[In the modern world of abundance of information through various sources and platforms, patients are increasingly looking for greater engagement in their healthcare decision-making process with the doctors, slowly but steadily, and in that process seeking better services from different &#8230; <a href="http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patient-services-arent-optional-any-more-for-pharma-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
